|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/24 Safeguard Scientifics Inc. 10-K 12/31/23 76:6.8M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.59M
2: EX-14.1 Code of Ethics HTML 108K
3: EX-21.1 Subsidiaries List HTML 23K
8: EX-97 Clawback Policy re: Recovery of Erroneously HTML 38K
Awarded Compensation
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
14: R1 Document And Entity Information HTML 86K
15: R2 Consolidated Balance Sheets HTML 127K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 33K
17: R4 Consolidated Statements of Operations HTML 75K
18: R5 Consolidated Statements of Changes in HTML 72K
Shareholders' Equity
19: R6 Consolidated Statements of Cash Flows HTML 92K
20: R7 Note 1 - General HTML 73K
21: R8 Note 2 - Ownership Interests and Advances HTML 77K
22: R9 Note 3 - Acquisitions of Ownership Interests HTML 30K
23: R10 Note 4 - Fair Value Measurements HTML 59K
24: R11 Note 5 - Equity HTML 32K
25: R12 Note 6 - Stock-Based Compensation HTML 80K
26: R13 Note 7 - Employee Benefit Plan HTML 25K
27: R14 Note 8 - Income Taxes HTML 58K
28: R15 Note 9 - Net Income (Loss) Per Share HTML 40K
29: R16 Note 10 - Related Party Transactions HTML 27K
30: R17 Note 11 - Commitments and Contingencies HTML 32K
31: R18 Note 12 - Supplemental Cash Flow Information HTML 25K
32: R19 Note 13 - Segment Reporting HTML 29K
33: R20 Note 14 - Selected Quarterly Financial Information HTML 81K
(Unaudited)
34: R21 Note 15 - Subsequent Events HTML 25K
35: R22 Insider Trading Arrangements HTML 30K
36: R23 Significant Accounting Policies (Policies) HTML 100K
37: R24 Note 1 - General (Tables) HTML 44K
38: R25 Note 2 - Ownership Interests and Advances (Tables) HTML 75K
39: R26 Note 4 - Fair Value Measurements (Tables) HTML 56K
40: R27 Note 6 - Stock-Based Compensation (Tables) HTML 71K
41: R28 Note 8 - Income Taxes (Tables) HTML 54K
42: R29 Note 9 - Net Income (Loss) Per Share (Tables) HTML 36K
43: R30 Note 14 - Selected Quarterly Financial Information HTML 79K
(Unaudited) (Tables)
44: R31 Note 1 - General (Details Textual) HTML 30K
45: R32 Note 1 - General - Schedule of Restrictions on HTML 29K
Cash and Cash Equivalents (Details)
46: R33 Note 1 - General - Schedule of Leases (Details) HTML 53K
47: R34 Note 2 - Ownership Interests and Advances (Details HTML 50K
Textual)
48: R35 Note 2 - Ownership Interests and Advances - HTML 36K
Schedule of Carrying Value of Ownership Interests
(Details)
49: R36 Note 2 - Ownership Interests and Advances - HTML 31K
Schedule of Ownership Interests (Details)
50: R37 Note 2 - Ownership Interests and Advances - HTML 73K
Schedule of Equity Method Investment Partner
Company Results Of Operation (Details)
51: R38 Note 2 - Ownership Interests and Advances - HTML 49K
Schedule of Results of Operations (Details)
52: R39 Note 3 - Acquisitions of Ownership Interests HTML 51K
(Details Textual)
53: R40 Note 4 - Fair Value Measurements (Details Textual) HTML 25K
54: R41 Note 4 - Fair Value Measurements - Fair Value of HTML 41K
Assets and Liabilities Measured On Recurring Basis
(Details)
55: R42 Note 5 - Equity (Details Textual) HTML 43K
56: R43 Note 6 - Stock-Based Compensation (Details HTML 73K
Textual)
57: R44 Note 6 - Stock-based Compensation - Schedule of HTML 24K
Stock-based Compensation Expense (Details)
58: R45 Note 6 - Stock-Based Compensation - Schedule of HTML 59K
Stock Options Activity (Details)
59: R46 Note 6 - Stock-Based Compensation - Schedule of HTML 43K
Restricted Stock Units Deferred Stock Units and
Performance Units (Details)
60: R47 Note 7 - Employee Benefit Plan (Details Textual) HTML 26K
61: R48 Note 8 - Income Taxes (Details Textual) HTML 31K
62: R49 Note 8 - Income Taxes - Schedule of Effective HTML 29K
Income Tax Rate Reconciliation (Details)
63: R50 Note 8 - Income Taxes -Schedule of Deferred Tax HTML 42K
Assets and Liabilities (Details)
64: R51 Note 8 - Income Taxes - Schedule of Summary of HTML 31K
Operating Loss Carryforwards (Details)
65: R52 Note 9 - Net Income (Loss) Per Share (Details HTML 35K
Textual)
66: R53 Note 9 - Net Income (Loss) Per Share - HTML 60K
Calculations of Net Income (Loss) Per Share
(Details)
67: R54 Note 11 - Commitments and Contingencies (Details HTML 36K
Textual)
68: R55 Note 12 - Supplemental Cash Flow Information HTML 22K
(Details Textual)
69: R56 Note 13 - Segment Reporting (Details Textual) HTML 22K
70: R57 Note 14 - Selected Quarterly Financial Information HTML 71K
(Unaudited) - Schedule of Selected Quarterly
Financial Information (Unaudited) (Details)
71: R58 Note 15 - Subsequent Events (Details Textual) HTML 32K
73: XML IDEA XML File -- Filing Summary XML 136K
76: XML XBRL Instance -- sfe20231231_10k_htm XML 1.28M
72: EXCEL IDEA Workbook of Financial Report Info XLSX 97K
10: EX-101.CAL XBRL Calculations -- sfe-20231231_cal XML 138K
11: EX-101.DEF XBRL Definitions -- sfe-20231231_def XML 993K
12: EX-101.LAB XBRL Labels -- sfe-20231231_lab XML 870K
13: EX-101.PRE XBRL Presentations -- sfe-20231231_pre XML 1.04M
9: EX-101.SCH XBRL Schema -- sfe-20231231 XSD 170K
74: JSON XBRL Instance as JSON Data -- MetaLinks 373± 600K
75: ZIP XBRL Zipped Folder -- 0001437749-24-009415-xbrl Zip 321K
Exhibit 31.2
CERTIFICATION
I, Mark R. Dow, certify that:
|
1. |
I have reviewed this Annual Report on Form 10-K of Safeguard Scientifics, Inc.; |
|
|
|
|
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
|
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
|
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
|
|
|
|
|
a. |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
|
b. |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
|
c. |
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
|
d. |
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
|
|
|
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
|
|
|
|
|
a. |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
|
|
|
b. |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
|
|
SAFEGUARD SCIENTIFICS, INC. |
|
|
|
|
|
Date |
March 26, 2024 |
/s/ Mark R. Dow |
|
|
|
|
|
|
|
Chief Financial Officer and Secretary |
|
|
|
(Principal Financial and Accounting Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/26/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||